<DOC>
	<DOCNO>NCT02022696</DOCNO>
	<brief_summary>This clinical gene transfer study aim verify safety efficacy use EFS-ADA lentiviral vector introduce human adenosine deaminase ( ADA ) gene hematopoietic progenitor patient affect severe combine immunodeficiency due ADA deficiency . The EFS-ADA vector express human ADA cDNA control elongation factor alpha short promoter ( EFS ) . In addition , protocol examine effect ADA gene transfer immune system treat patient . Patients ADA deficiency ineligible match sibling allogeneic bone marrow transplantation eligible participate study . To increase engraftment select advantage gene-corrected cell , busulfan use cytoreductive agent . Enzyme replacement ( PEG-ADA ) discontinue 30 day infusion gene-corrected cell . CD34+ hematopoietic progenitor isolate patient bone marrow , peripheral blood cord blood , expose lentiviral vector-mediated gene transfer re-infused patient peripheral vein . Clinical , immunological molecular follow-up study ass safety , toxicity , efficacy procedure .</brief_summary>
	<brief_title>Treatment SCID Due ADA Deficiency With Autologous Transplantation Cord Blood Hematopoietic CD 34+ Cells After Addition Normal Human ADA cDNA EFS-ADA Lentiviral Vector</brief_title>
	<detailed_description>This clinical gene transfer study aim verify safety efficacy use EFS-ADA lentiviral vector introduce human adenosine deaminase ( ADA ) gene hematopoietic progenitor patient affect severe combine immunodeficiency due ADA deficiency . The EFS-ADA vector express human ADA cDNA control elongation factor alpha short promoter ( EFS ) . In addition , protocol examine effect ADA gene transfer immune system treat patient . Patients ADA deficiency ineligible match sibling allogeneic bone marrow transplantation eligible participate study . To increase engraftment select advantage gene-corrected cell , busulfan use cytoreductive agent . Enzyme replacement ( PEG-ADA ) discontinue 30 day infusion gene-corrected cell . CD34+ hematopoietic progenitor isolate patient bone marrow , peripheral blood cord blood , expose lentiviral vector-mediated gene transfer re-infused patient peripheral vein . Clinical , immunological molecular follow-up study ass safety , toxicity , efficacy procedure .</detailed_description>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<criteria>INCLUSION CRITERIA : Participants must satisfy Inclusion Criteria I , II , III . I . Children great equal 1.0 month age diagnosis ADAdeficient SCID base : A . Confirmed absence ( &lt; 3 % normal level ) ADA enzymatic activity peripheral blood ( neonate ) umbilical cord erythrocytes and/or leukocyte , skin fibroblast culture fetal cell derive either chorionic villus biopsy amniocentesis , prior institution enzyme replacement therapy . AND B . Evidence severe combine immunodeficiency base either : 1 . Family history first order relative ADA deficiency clinical laboratory evidence severe immunologic deficiency , OR 2 . Evidence severe immunologic deficiency subject prior institution immune restorative therapy , base lymphopenia ( absolute lymphocyte count &lt; 200/microliters ) severely decrease T lymphocyte blastogenic response phytohemagglutinin ( DeltaCPM &lt; 5,000 ) , II . Ineligible match sibling allogeneic bone marrow transplantation due absence medically eligible HLAidentical sibling normal immune function may serve allogeneic bone marrow donor . III . Signed write informed consent accord guideline UCLA Office Human Research Protection Program National Human Genome Research Institute ( NHGRI ) Institutional Review Boards . It policy NIH Clinical Center admit patient young 1 year age weigh less 10 kg inadequacy exist emergency intensive care service young child . We comply policy . EXCLUSION CRITERIA ( OBSERVED WITHIN 8 WEEKS OF ENTERING THIS TRIAL ) : 1 . Age less equal 1.0 month 2 . Hematologic 1 . Anemia ( hemoglobin &lt; 10.5 g/dl &lt; 2 year age , &lt; 11.5 g/dl &gt; 2 year age ) . 2 . Neutropenia ( absolute granulocyte count &lt; 500/mm ( 3 ) . If ANC &lt; 1,000 , absence myelodysplastic syndrome bone marrow aspirate biopsy normal marrow cytogenetics . 3 . Thrombocytopenia ( platelet count &lt; 150,000/mm ( 3 ) , age ) . 4 . PT PTT &gt; 2 time upper limit normal ( patient correctable deficiency control medication exclude ) . 5 . Cytogenetic abnormality peripheral blood bone marrow amniotic fluid ( available ) . 3 . Infectious . Evidence active opportunistic infection infection HIV1 , hepatitis B , CMV parvovirus B 19 DNA PCR within 3090 day prior bone marrow harvest . 4 . Pulmonary 1 . Resting O2 saturation pulse oximetry &lt; 95 % room air . 2 . Chest xray indicate active progressive pulmonary disease . 5 . Cardiac 1 . Abnormal electrocardiogram ( EKG ) indicate cardiac pathology . 2 . Uncorrected congenital cardiac malformation clinical symptomatology . 3 . Active cardiac disease , include clinical evidence congestive heart failure , cyanosis , hypotension . 4 . Poor cardiac function evidence LV ejection fraction &lt; 40 % echocardiogram . 6 . Neurologic 1 . Significant neurologic abnormality examination . 2 . Uncontrolled seizure disorder . 7 . Renal 1 . Renal insufficiency : serum creatinine great equal 1.2 mg/dl , great equal 3+ proteinuria . 2 . Abnormal serum sodium , potassium , calcium , magnesium , phosphate grade III IV Division AIDS Toxicity Scale . 8 . Hepatic/GI : 1 . Serum transaminases &gt; 5 time upper limit normal ( ULN ) . 2 . Serum bilirubin &gt; 2 time ULN . 3 . Serum glucose &gt; 1.5 time ULN . 4 . Intractable severe diarrhea . 9 . Oncologic 1 . Evidence active malignant disease dermatofibrosarcoma protuberans ( DFSP ) * 2 . Evidence DFSP expect require antineoplastic therapy within 5 year follow infusion genetically correct cell 3 . Evidence DFSP expect life limit within 5 year follow infusion genetically correct cell 10 . Known sensitivity Busulfan 11 . General 1 . Expected survival &lt; 6 month . 2 . Pregnant . 3 . Major congenital anomaly . 4 . Ineligible autologous HSCT criterion clinical site . 5 . Other condition opinion principal investigator and/or coinvestigators , contraindicate bone marrow harvest , administration busulfan , infusion transduce cell indicate patient patient parents/primary caregiver inability follow protocol . DFSP rare , locally invasive tumor low metastatic potential . Patients receive active antineoplastic therapy cancer , include DFSP , eligible . Patients DFSP treat active antineoplastic therapy time enrollment AND plan receive active antineoplastic therapy absence progressive malignant disease AND whose DFSP expect lifelimiting within five year follow infusion genetically correct cell eligible . Patients DFSP , radiation chemotherapy chosen , would remain ineligible treatment , interaction busulfan experimental gene transfer vector active antineoplastic therapy difficult predict could reasonably expect deleterious due overlap toxicity . When antineoplastic therapy conclude , patient ADASCID history DFSP include .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 6, 2017</verification_date>
	<keyword>Adenosine Deaminase Deficiency</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Lentiviral Vectors</keyword>
</DOC>